3-cyclopropyl-5-nitro-1H-pyrazole | 326827-23-0

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 3-cyclopropyl-5-nitro-1H-pyrazole
• CAS: 326827-23-0
• 化学式: C₆H₇N₃O₂
• mdl: MFCD09701702
• 分子量: 153.14
• InChiKey: CTSMOTWWAYPQLU-UHFFFAOYSA-N

物化性质

• 沸点：
  351.1±30.0 °C(Predicted)
• 密度：
  1.519±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  74.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090

反应信息

• 作为反应物：
  描述：

  3-cyclopropyl-5-nitro-1H-pyrazole 在 palladium on activated charcoal 、 四丁基氟化铵 、 氢气 、 potassium carbonate 、 三乙胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 35.0h， 生成 (trans)-3-(benzo[d]thiazol-4-yloxy)-N-(3-cyclopropyl-1H-pyrazol-5-yl)cyclobutanecarboxamide
  参考文献：
  名称：

  [EN] 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS
  [FR] DÉRIVÉS D'AZÉTIDINE OU DE CYCLOBUTANE 1,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROSTAGLANDINE D SYNTHASE HÉMATOPOÏÉTIQUE (H-PGDS)

  摘要：

  式（I）的化合物，其中R、R1、R2、R3、Y、Y1、a、X和Z的定义如本文所述。本发明的化合物是造血前列腺素D合成酶（H-PGDS）的抑制剂，可用于治疗杜兴氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗相关疾病的方法。

  公开号：

  WO2018069863A1
• 作为产物：
  描述：

  3-氨基-5-环丙基-1H-吡唑 在 sodium hydroxide 、 Oxone 、 碳酸氢钠 作用下， 以 水 、 丙酮 为溶剂， 反应 4.0h， 以56%的产率得到3-cyclopropyl-5-nitro-1H-pyrazole
  参考文献：
  名称：

  3-Acylaminopyrazole derivatives via a regioselectively N-protected 3-nitropyrazole

  摘要：

  A simple procedure for the selective protection of the enclocyclic 1-N of 3-aminopyrazoles as tert-butoxycarbamate (Boc) in good yield is described. A 3-nitropyrazole derivative represents the key intermediate with the nitro substituent determining the regiochemistry of the obtained protected Compound. Subsequent acylation at the exocyclic amino group gave rise, after Bee removal, to a series of 3-acylaminopyrazoles in high yields and purities. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.12.054

文献信息

• 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
  申请人：Pharmacia & Upjohn S.p.A.

  公开号：US06387900B1

  公开（公告）日：2002-05-14

  3-ureido-pyrazole derivatives represented by formula (I): where R, R1 and R2 are as described herein, or pharmnaceutically acceptable salts thereof; are useful, for example, for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.

  以式(I)所表示的3-尿酰基吡唑衍生物：其中R、R1和R2如本文所述，或其药学上可接受的盐；例如，对于癌症、细胞增殖紊乱、阿尔茨海默病、病毒感染、自身免疫疾病或神经退行性疾病的治疗是有用的。
• 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
  申请人：Pharmacia & Upjohn S.p.A

  公开号：US06218418B1

  公开（公告）日：2001-04-17

  Compounds which are 3-amino-pyrazole derivatives represented by formula (I): where R is a C3-C6 cycloalkyl group, which may optionally be substituted by a straight or branched C1-C6 alkyl group, and R1 is a straight or branched C1-C6 alkyl group or a C2-C4 alkenyl, cycloalkyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl and arylalkenyl, which may be optionally substituted; or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.

  化合物是由式（I）表示的3-氨基吡唑衍生物，其中R是C3-C6环烷基，可以选择地被直链或支链的C1-C6烷基取代，而R1是直链或支链的C1-C6烷基或C2-C4烯基、环烷基、芳基、芳基烷基、芳基羰基、芳基氧烷基和芳基烯基，可以选择地被取代；或其药学上可接受的盐。这些化合物可用于治疗癌症、细胞增殖紊乱、阿尔茨海默病、病毒感染、自身免疫疾病或神经退行性疾病。
• [EN] 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS<br/>[FR] DERIVES DE 3(5)-AMINO-PYRAZOLE, LEUR PROCEDE DE FABRICATION ET LEUR EMPLOI COMME AGENTS ANTI-TUMORAUX
  申请人：PHARMACIA & UPJOHN SPA

  公开号：WO2001012189A1

  公开（公告）日：2001-02-22

  Compounds which are 3-amino-pyrazole derivatives represented by formula (I) wherein R is C3-C6 cycloalkyl group optionally substituted by a straight or branched C1-C6 alkyl or arylalkyl group; R1 is a straight or branched C1-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl or arylalkenyl group, each of which may be optionally further substituted as indicated in the description; or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.

  化合物是由式（I）表示的3-氨基吡唑衍生物，在该式中，R是C3-C6环烷基，可以选择性地被直链或支链的C1-C6烷基或芳基烷基取代；R1是直链或支链的C1-C6烷基，C2-C4烯基，环烷基，环烯基，杂环烷基，芳基，芳基烷基，芳基羰基，芳氧基烷基或芳基烯基基团，每个基团可以选择性地进一步按照说明中所示取代；或其药学上可接受的盐。这些化合物可用于治疗癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病或神经退行性疾病。
• 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US11053234B2

  公开（公告）日：2021-07-06

  A compound of formula (I) wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式 (I) 的化合物 其中 R、R1、R2、R3、Y、Y1、a、X 和 Z 如本文所定义。 本发明的化合物是造血前列腺素 D 合酶（H-PGDS）的抑制剂，可用于治疗杜氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物抑制 H-PGDS 活性和治疗相关疾病的方法。
• 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS
  申请人：Pfizer Italia S.r.l.

  公开号：EP1202734B1

  公开（公告）日：2007-05-02